Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancerJosé A García-Sáenz
Servicio de Oncologia Medica, Hospital Clinico San Carlos, Madrid, Spain
Clin Breast Cancer 6:325-9. 2005
..To determine the activity of successive trastuzumab-containing regimens in HER2-overexpressing metastatic breast cancer (MBC) as well as the response rate (RR), time to progression (TTP), and predictive factors for response...
- Significance of the immunohistochemical detection of lymph node micrometastases in stage II colorectal carcinoma
José A García-Sáenz
Oncology Department, Hospital Clinico San Carlos, Madrid, Spain
Clin Transl Oncol 8:676-80. 2006
..Immunohistochemistry is being explored to detect undetectable microscopic lymph node micrometastases...
- Circulating tumoral cells lack circadian-rhythm in hospitalized metastasic breast cancer patients
Jose Angel Garcia-Saenz
Servicio de Oncología Médica Hospital Universitario San Carlos Madrid Spain
Clin Transl Oncol 8:826-9. 2006
..The relationship between breast cancer and circadian rhythm variation has been extensively studied. Increased breast tumorigenesis has been reported in melatonin-suppressed experimental models and in observational studies...
- Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid
Jose Angel Garcia Saenz
Servicio de Oncologia Medica, Hospital Universitario San Carlos, Madrid, Spain
Med Oral Patol Oral Cir Bucal 12:E351-6. 2007
..Here we report our findings on all 2005 OJN cases presented at our institution resulting from bone metastatic prostate cancer treated with zoledronic acid. The incidence of ONJ is nearly 3% (3 out of 104) in these patients...
- Circulating tumour cells in locally advanced breast cancer
Jose Angel Garcia-Saenz
Servicio de Oncologia Medica, Hospital Universitario San Carlos, Madrid, Spain
Clin Transl Oncol 11:544-7. 2009
..Two blood samples were obtained from 72 eligible LABC patients to isolate and enumerate CTCs before neoadjuvant chemotherapy started on day 1, and on day 21, immediately before second cycle administration...
- Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer
José A García-Sáenz
Servicio de Oncologia Medica, Hospital Clinico Universitario San Carlos, Madrid, Spain
Clin Transl Oncol 11:737-47. 2009
..Such patterns may be a novel and cost-effective tool to develop tailored treatments. This manuscript will review biomarkers and molecular pathways that are involved in the tumour response to anti-EGFR therapies...
- Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies
Javier Puente Vázquez
Servicio de Oncologia Medica, Hospital Clinico San Carlos, Madrid, Spain
Clin Transl Oncol 8:50-3. 2006
..CNS metastases mean a great challenge. It has been suggested that the brain metastases incidence could be high in metastasic breast cancer patients receiving trastuzumab based-therapies...
Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature reviewJosé A García-Sáenz
Medical Oncology Department, Hospital Clinico San Carlos, Madrid, Spain
Clin Transl Oncol 13:121-32. 2011
..Suboptimal survival results have led to major efforts to identify prognostic factors, improve surgical staging and develop adjuvant therapies to improve patients' outcomes...
- Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: a cooperative study by the GEICAM group
Carlos Jara-Sánchez
Unidad de Oncología Médica, Fundacion Hospital Alcorcon, Madrid, Spain
Clin Breast Cancer 3:399-404. 2003
..However, the results do not indicate clear advantages compared to the conventional weekly scheme of administration...
